No. 42-2, May 2004
Index
- Competitive Costs of Disclosure by Biotech IPOs
- Disclosure Practices of Foreign Companies Interacting with U.S. Markets
- Discussion of Competitive Costs of Disclosure by Biotech IPOs
- Discussion of Disclosure Practices of Foreign Companies Interacting with U.S. Markets
- Discussion of Firms' Voluntary Recognition of Stock‐Based Compensation Expense
- Discussion of Information Transparency and Coordination Failure: Theory and Experiment
- Discussion of Investor Protection and Corporate Governance: Evidence from CEO Turnover
- Discussion of Ultimate Ownership, Income Management, and Legal and Extra‐Legal Institutions
- Discussion of Underwater Options and the Dynamics of Executive Pay‐to‐Performance Sensitivities
- Discussion of What Determines Corporate Transparency?
- Firms' Voluntary Recognition of Stock‐Based Compensation Expense
- Information Transparency and Coordination Failure: Theory and Experiment
- Investor Protection and Corporate Governance: Evidence from Worldwide CEO Turnover
- Ultimate Ownership, Income Management, and Legal and Extra‐Legal Institutions
- Underwater Options and the Dynamics of Executive Pay‐to‐Performance Sensitivities
- What Determines Corporate Transparency?